On Tuesday, Apogee Therapeutics Inc (NASDAQ: APGE) was -1.41% drop from the session before settling in for the closing price of $49.07. A 52-week range for APGE has been $19.91 – $72.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 7.87%. With a float of $36.28 million, this company’s outstanding shares have now reached $45.02 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Apogee Therapeutics Inc stocks. The insider ownership of Apogee Therapeutics Inc is 37.99%, while institutional ownership is 80.61%. The most recent insider transaction that took place on Dec 04 ’24, was worth 307,057. In this transaction Chief Medical Officer of this company sold 6,665 shares at a rate of $46.07, taking the stock ownership to the 260,798 shares. Before that another transaction happened on Dec 04 ’24, when Company’s Chief Executive Officer sold 15,000 for $46.58, making the entire transaction worth $698,654. This insider now owns 1,324,487 shares in total.
Apogee Therapeutics Inc (APGE) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.87% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
You can see what Apogee Therapeutics Inc (APGE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 16.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -4.32 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Apogee Therapeutics Inc (NASDAQ: APGE) saw its 5-day average volume 0.75 million, a positive change from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 56.64%. Additionally, its Average True Range was 3.32.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 37.91%, which indicates a significant decrease from 53.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.64% in the past 14 days, which was higher than the 60.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.28, while its 200-day Moving Average is $50.60. Nevertheless, the first resistance level for the watch stands at $49.36 in the near term. At $50.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $51.04. If the price goes on to break the first support level at $47.67, it is likely to go to the next support level at $46.97. The third support level lies at $45.99 if the price breaches the second support level.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
There are 45,027K outstanding shares of the company, which has a market capitalization of 2.83 billion. As of now, sales total 0 K while income totals -83,990 K. Its latest quarter income was 0 K while its last quarter net income were -49,020 K.
